0 rating

Systemic Sclerosis

Smith V, Van Praet JT, Vandooren B et al.

Ghent University Hospital, Ghent, Belgium.

 Ann Rheum Dis 2010;69:193–7.

Editor’s note: In this open-label trial, the authors sought to evaluate the safety of rituximab in patients with diffuse cutaneous systemic sclerosis (dc-SSc). In recent years, there has been an increasing interest in the efficacy and safety of this anti-CD20 monoclonal antibody in the treatment of autoimmune disorders. However, in the field of dc-SSc, the information is limited.

Return to top

LATEST ARTICLES

Our most popular articles